• Pluristem Therapeutics Inc (NASDAQ: PSTI) has received €20 million (approximately $24 million) from the European Investment Bank (EIB), the first disbursement of three tranches of funding.

• The disbursement reflects that Pluristem has achieved a key milestone in a previously announced €50 million non-dilutive financing agreement.

• Under the EIB agreement, Pluristem expects to receive the first tranche of funds during June 2021.

• The proceeds of the first tranche will support R&D in Europe to advance Pluristem's proprietary regenerative cell therapy platform.

• The first tranche of €20 million will be unsecured and payable to the EIB in a single payment five years after the disbursement, with an interest rate of 4%.

• Following the receipt of the €20 million tranche, Pluristem will have a cash balance of more than $90 million.

• Price Action: PSTI shares are up 6.58% at $4.05 during the premarket session on the last check Tuesday.

See more from Benzinga

• Click here for options trades from Benzinga

• Moderna's COVID-19 Vaccine Effective at Preventing Infection in Adolescents

• TLC Stock Jumps on India's Approval of Liposomal Amphotericin B As Black Fungus Treatment

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.